Performance-based quality specifications: the relationship between process critical control parameters, critical...

Area of Science:

• Pharmaceutical Quality Control
• Drug Manufacturing
• Pharmacokinetics and Pharmacodynamics

Background:

• Current pharmaceutical quality control relies on tests that do not directly assess clinical consequences of product variability.
• Existing methods lack the ability to quantify risks of drug inefficacy or toxicity stemming from manufacturing variations.

Purpose of the Study:

• To evaluate the adequacy of United States Pharmacopeia (USP) <711> and <905> specifications for extended-release theophylline tablets.
• To assess the clinical implications of content uniformity and dissolution variability on drug efficacy and toxicity.
• To develop an improved methodology for defining pharmaceutical design spaces based on direct clinical performance metrics.

Main Methods:

• Utilized a previously established risk simulation platform to generate quantitative estimates of inefficacy and toxicity.
• Simulated 288 uniform lots of extended-release theophylline tablets with varying content uniformity and dissolution profiles.
• Evaluated USP univariate specifications and developed new design spaces using content uniformity and Weibull dissolution time constants.

Main Results:

• USP content uniformity specifications were found to be too lenient, increasing risks of both inefficacy and toxicity.
• USP dissolution testing criteria were too strict for inefficacy but inaccurate for toxicity assessment.
• The study identified limitations in USP tests for capturing the combined impact of content uniformity and dissolution variability.

Conclusions:

• Current USP specifications for drug quality attributes are insufficient for predicting clinical outcomes.
• A simulation-based approach using direct clinical performance metrics offers a more informative method for defining drug design spaces.
• This enhanced methodology moves beyond surrogate quality attributes to directly link product attributes to patient safety and drug effectiveness.